Scarica l'app Stockscreener
3.78
5.00%
0.18
Dopo l'orario di chiusura:
3.53
-0.25
-6.61%
Precedente Chiudi:
$3.60
Aprire:
$3.6
Volume 24 ore:
80,687
Relative Volume:
2.88
Capitalizzazione di mercato:
$176.81M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.82%
1M Prestazione:
-7.80%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.50
$3.8398
Intervallo di 1 settimana:
$3.50
$3.99
Portata 52W:
$3.50
$4.8816
Capsovision Inc Stock (CV) Company Profile
Nome
Capsovision Inc
Settore
Industria
Telefono
(408) 370-4790
Indirizzo
18805 COX AVENUE SUITE 250, SARATOGA
Confronta CV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
3.78 | 170.73M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
132.81 | 228.80B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.29 | 158.04B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.34 | 149.08B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.85 | 119.71B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
80.96 | 48.01B | 5.69B | 1.41B | 577.90M | 6.95 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Roth Capital | Buy |
| 2025-07-28 | Iniziato | The Benchmark Company | Speculative Buy |
Capsovision Inc Borsa (CV) Ultime notizie
CapsoVision chief financial officer steps down; company begins search for successor - Investing.com
CapsoVision CFO Kevin Lundquist Resigns - MarketWatch
Capsovision says Kevin Lundquist steps down as CFOSEC filing - MarketScreener
CapsoVision CFO Kevin Lundquist Steps Down - TipRanks
Ingestible Sensors Market Set for Dynamic Growth with Key Players CapsoVision, Inc., BodyCAP, etectRx - openPR.com
Head to Head Comparison: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Smart Pills Market Worth US$1.30 Billion By 2030 With 11.2% CAGR - Barchart.com
Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR - openPR.com
FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital - MarketBeat
Critical Analysis: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Insider Transactions Reported | CapsoVision(CV)saw insider trading activity on 8/22/2025 - AInvest
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Issues Earnings Results - MarketBeat
CapsoVision 2025 Q2 Earnings Net Loss Narrows 12.2% - AInvest
CapsoVision Reports Second Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Reports Revenue Growth and IPO Success - TipRanks
CapsoVision Revenue Jumps 17 Percent - AOL.com
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies - Yahoo Finance
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV) - MarketBeat
CapsoVision, Inc.’s (NASDAQ:CV) Quiet Period Will End on August 11th - Defense World
Is capsovision scam - AInvest
Roth Capital Predicts CapsoVision's Q2 Earnings (NASDAQ:CV) - MarketBeat
CapsoVision (NASDAQ:CV) Raised to Strong-Buy at Roth Capital - MarketBeat
Understanding the risks associated with CapsoVision's stock - AInvest
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewswire
Capsovision, Inc. shares fall 2.19% intraday as Kioxia Corporation announces new UFS 4.1 devices for automotive applications. - AInvest
Q2 Earnings Estimate for CapsoVision Issued By Roth Capital - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
CapsoVision (NASDAQ:CV) Rating Increased to Strong-Buy at Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Upgraded at Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Upgraded by Roth Capital to Strong-Buy Rating - Defense World
CapsoVision (NASDAQ:CV) Raised to “Strong-Buy” at Roth Capital - Defense World
Capsovision, Inc. shares rise 3.45% intraday after Canon Inc. announces share buyback plan. - AInvest
CapsoVision is a buy, this analyst says - Cantech Letter
Capsovision, Inc. shares fall 1.15% premarket after Canon Inc. announced a buyback plan. - AInvest
CapsoVision (NASDAQ:CV) Earns Speculative Buy Rating from Analysts at Benchmark - MarketBeat
Benchmark Co. Initiates CapsoVision(CV.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
CapsoVision: Benchmark initiates coverage with Speculative Buy rating, $5 price target. - AInvest
CapsoVision stock initiated with Speculative Buy rating at Benchmark By Investing.com - Investing.com Australia
Benchmark starts CapsoVision with a Speculative Buy as CapsoCam Plus takes share - TipRanks
CapsoVision initiated with a Buy at Roth Capital - TipRanks
CapsoVision stock initiated with Buy rating at Roth/MKM on GI imaging potential - Investing.com Nigeria
CapsoVision stock initiated with Speculative Buy rating at Benchmark - Investing.com
CapsoVision Completes $27.5 Million Nasdaq IPO - Global Legal Chronicle
CapsoVision enters development agreement with Canon and announces partial IPO overallotment exercise - Investing.com India
Capsovision Inc Azioni (CV) Dati Finanziari
Non sono disponibili dati finanziari per Capsovision Inc (CV). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.38%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):